The CiteAb Innovation Award highlights an innovative product which has satisfied a gap in the market or solved a known issue within the respective field. The product must have been launched in the past 12 months.

Many congratulations to Abcam, winners of The Innovation Award with their newly launched recombinant multiclonal range!

This category was extremely close, with many fascinating innovations entered and multiple nominations receiving high scores from our judges. In the end, Abcam’s recombinant multiclonal range stood out from the other entries.

Their innovative new category of antibodies combine the specificity of monoclonals with the improved assay/detection signal of polyclonals, overcoming the difficulty with selecting one or the other for an experiment.

To achieve this, the recombinant multiclonal range consists of a defined mixture of selected recombinant monoclonal antibodies designed to recognise different epitopes on the same antigen.

On top of this, by utilising recombinant production this range solves the problem of genetic drift associated with hybridoma production with traditional monoclonals, and ensures high batch to batch consistency.

Dr Andrew Chalmers, CEO and founder of CiteAb said ‘This product really supports reproducibility in the sector which will benefit the global research community. Abcam zoned in on a challenge in the industry and offered a solution, making them a very deserving winner of this award!’

The judges